LRMR Larimar Therapeutics, Inc.

CIK 0001374690 50 ready 8-Ks latest August 4, 2026, 7:02 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 4, 2026, 7:02 AM ET

Top materiality 0.85

Event mix other_material ×23 · earnings ×10 · regulatory ×7

Sentiment 21 pos · 1 neg · 28 neu

Latest earnings ▼ miss 2025-Q3

Executive change recent →

Recent 8-K filings for LRMR

Highest-materiality recent filing

Larimar submits BLA module for nomlabofusp accelerated approval; positive open-label data in Friedreich's ataxia

June 29, 2026, 6:33 AM ET regulatory materiality 0.85 positive item 8.01 item 9.01

Submitted first module of rolling BLA to FDA for accelerated approval of nomlabofusp; FDA confirmed existing data appears sufficient.
Open-label study: 100% (9/9) of participants achieved skin FXN levels >50% of healthy volunteer mean at 1 year.

Read filing →

August 4, 2026, 7:02 AM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

Larimar Q2 net loss $32.8M; nomlabofusp BLA rolling submission underway

Net loss $32.8M ($0.30/sh) vs $26.2M ($0.41/sh) in Q2 2025; cash $156.3M, runway into Q3 2027.
June 29, 2026, 6:33 AM ET regulatory materiality 0.85 positive item 8.01 item 9.01

Larimar submits BLA module for nomlabofusp accelerated approval; positive open-label data in Friedreich's ataxia

Submitted first module of rolling BLA to FDA for accelerated approval of nomlabofusp; FDA confirmed existing data appears sufficient.
May 14, 2026, 7:02 AM ET other material materiality 0.85 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M

Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.
March 19, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission

Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.
February 27, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

Larimar Therapeutics prices 20M share public offering at $5.00 per share; underwriters exercise over-allotment

Offering of 20,000,000 shares plus 3,000,000 over-allotment shares at $5.00 per share.
February 24, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Larimar Therapeutics receives FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich's ataxia

FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia.
November 5, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study

Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.
September 29, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN

10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).
August 14, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 8.01 item 9.01

Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026

Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.
July 31, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 9.01

Larimar Therapeutics prices $64.4M common stock offering at $3.20 per share

Offering of 18,750,000 shares of common stock at $3.20; underwriters' over-allotment of 2,812,500 shares exercised in full.
June 23, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Larimar gets FDA safety database guidance; nomlabofusp BLA submission planned for Q2 2026

FDA recommends safety database of ≥30 participants with 6-month continuous exposure (≥10 with 1-year), majority on 50 mg dose.
April 30, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint

Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.
March 24, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 2.02 item 8.01 item 9.01

Larimar reports FDA open to FXN as surrogate endpoint; BLA submission on track for end-2025

FDA considers skin FXN concentration reasonably likely surrogate endpoint for accelerated approval of nomlabofusp in Friedreich's ataxia.
December 16, 2024, 6:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

Larimar reports positive OLE data: FXN up to 30% of healthy in buccal cells at Day 90; BLA filing targeted 2H 2025

Mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90.
October 30, 2024, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 8.01 item 9.01

Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025

Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.
August 7, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 8.01 item 9.01

Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program

Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.
May 20, 2024, 7:59 PM ET regulatory materiality 0.80 positive item 8.01 item 9.01

FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia

FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.
May 9, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025

Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.
March 14, 2024, 7:59 PM ET other material materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Larimar reports positive Phase 2 data for nomlabofusp; $161.6M financing extends runway into 2026

Phase 2 dose exploration study met endpoints: dose-dependent frataxin increases in skin and buccal cells; 50 mg cohort saw levels >33% of healthy volunteers in all patients at Day 14.
March 11, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Larimar doses first patient in open-label extension study of nomlabofusp for Friedreich's ataxia

First patient dosed in OLE evaluating 25 mg daily subcutaneous nomlabofusp for Friedreich's ataxia.
February 16, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 9.01 ◈ Material Agreements

Larimar Therapeutics closes $161.8M public offering of 19.7M shares at $8.74

Offered 17,162,472 shares plus 2,574,370 option shares exercised immediately.
February 12, 2024, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 8.01 item 9.01

Larimar reports positive Phase 2 nomlabofusp data; frataxin dose response up to 5.57 pg/µg in skin

50 mg cohort: median FXN increase in skin 5.57 pg/µg at day 14; all patients reached >33% healthy volunteer level.
November 14, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Larimar completes Phase 2 50mg cohort enrollment; top-line data now Q1 2024; cash to Q1 2025

Completed enrollment and dosing of 50 mg cohort in Phase 2 FA trial; no serious adverse events observed (blinded).
August 10, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Larimar Therapeutics Q2 net loss $8.4M; FDA clears 50 mg cohort and OLE trial for CTI-1601 in FA

Net loss of $8.4M (-$0.19/share) vs $8.7M in Q2 2022; cash $104.2M, runway into Q4 2024.
July 25, 2023, 7:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

FDA clears Larimar's Phase 2 CTI-1601 trial to proceed to 50 mg cohort and OLE trial

FDA cleared Phase 2 dose exploration trial to proceed to 50 mg cohort; dosed daily for 14 days then every other day to day 28.
May 15, 2023, 7:59 PM ET other material materiality 0.85 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Larimar Phase 2 trial shows frataxin increases in skin and buccal cells; Q1 net loss $6.5M

Median placebo-adjusted frataxin increase from baseline: 3.5 pg/µg in skin, 0.9 pg/µg in buccal cells at day 14.

Executive changes

Appointed

Jeffrey W. Sherman

Class I Director

LRMR · Larimar Therapeutics, Inc.

Effective: 2023-10-03
Filed: October 3, 2023, 7:59 PM ET

On October 3, 2023 (the “ Appointment Date ”), the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”) increased the size of the Board from five to six members and, upon recommendation of the Nominating and Corporate Governance Committee, appointed Jeffrey W. Sherman, MD, FACP to serve as a Class I director, with an initial term expiring at the Company’s 2024 Annual Meeting of Stockholders, and a member of the Nominating and Corporate Governance Committee.

Departed

Peter Barrett

Director

LRMR · Larimar Therapeutics, Inc.

Effective: 2023-05-09
Filed: April 6, 2023, 7:59 PM ET

On April 3, 2023, Peter Barrett, Ph.D., a member of the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”), tendered his resignation from the Board to be effective as of May 9, 2023, the date of the Company’s 2023 Annual Meeting of Stockholders.

Departed

Thomas O. Daniel

Class II director

LRMR · Larimar Therapeutics, Inc.

Filed: April 11, 2022, 7:59 PM ET

On April 6, 2022, Thomas O. Daniel, Ph.D., a member of the Board of Directors (the “ Board ”) of Larimar Therapeutics, Inc. (the “ Company ”), notified the Company that he will not stand for re-election as a Class II director at the Company’s 2022 Annual Meeting of Stockholders (the “ Annual Meeting ”), and therefore, will no longer serve as a director of the Company or on any committee of the Board, effective as of the conclusion of the Annual Meeting.

Earnings & guidance

2025-Q3 EPS reported -$1.50 vs consensus -$0.41 ▼ miss (-264.0%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.62 · Most common event other_material

21 positive 1 negative 28 neutral

source · LRMR on sec.gov